Monoaminas Biogênicas/fisiologia; Transtorno Depressivo Maior/tratamento farmacológico; Vias Neurais/efeitos dos fármacos; Transmissão Sináptica/efeitos dos fármacos; Transmissão Sináptica/fisiologia; Animais; Antidepressivos/farmacologia; Antidepressivos/uso terapêutico; Encéfalo/efeitos dos fármacos; Encéfalo/fisiopatologia; Transtorno Depressivo Maior/fisiopatologia; Quimioterapia Combinada; Neuroimagem Funcional; Humanos; Modelos Neurológicos; Terapia de Alvo Molecular/métodos; Vias Neurais/fisiopatologia

5-HT; 5-hydroxytryptamine, serotonin; BDNF; CA; CNS; CO-MED; CRH; Cg25; Combining Medications to Enhance Depression Outcomes; DA; DAT; DRN; HAM-D; HPA; Hamilton Depression rating scale; LCSPT; MADRS; MAOIs; MDD; MRI; Major depressive disorder; Monoamine neurocircuitry; Montgomery-Åsberg Depression Rating Scale; Multimodal antidepressants; N-methyl-D-aspartate; NE; NET; NMDA; NRIs; OFC; PET; PRL; QIDS-SR; Quick Inventory of Depressive Symptomatology: Self Rated; ROI; ReHo; SERT; SNP; SNRIs; SR; SSRIs; Serotonin receptors; TCAs; Tph2; VTA; brain derived neurotrophic factor; catecholamines; central nervous system; corticotropin-releasing hormone; dopamine; dopamine transporter; dorsal raphe nucleus; fMRI; functional magnetic resonance imaging; hypothalamo-pituitary-adrenal (axis); limbic-cortical-striatal-pallidal-thalamic (circuits); magnetic resonance imaging; major depressive disorder; mixed serotonin and norepinephrine reuptake inhibitors; monoamine oxidase inhibitors; norepinephrine; norepinephrine transporter; orbitofrontal cortex; positron emission tomography; prolactin; regional homogeneity; regions of interest; selective norepinephrine reuptake inhibitors; selective serotonin reuptake inhibitors; serotonin transporter; single nucleotide polymorphism; subgenual cingulate (Brodmann area 25); sustained release; tricyclic antidepressants; tryptophan hydroxylase-2; ventral tegmentum area